Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03032965 · ClinicalTrials.gov registry record · Phase 2
Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
A Phase 2 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT03032965 is a Phase 2 study that has completed, run by University of Michigan. The registered enrollment target is 131 participants.
The verdict
NCT03032965, a Phase 2 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if additional ablation during the first procedure as the result of the ability to medically induce quiet atrial arrhythmias will improve clinical outcome in patients with atrial fibrillation thus decreasing the need for additional ablation procedures.
Interventions
- DRUG Isoproterenol
- DRUG Adenosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03032965
The ClinicalTrials.gov registry entry for NCT03032965 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Isoproterenol is the first listed.
NCT03032965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03032965 about?
NCT03032965 is a clinical study titled "Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation". The purpose of this study is to determine if additional ablation during the first procedure as the result of the ability to medically induce quiet atrial arrhythmias will improve clinical outcome in patients with atrial fibrillation thus decreasing the need for additional ablation procedures.
What is the current status of trial NCT03032965?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2011-10. Estimated completion is 2015-07.
What interventions are being tested in trial NCT03032965?
The interventions under investigation include: Isoproterenol (DRUG), Adenosine (DRUG).
Who is sponsoring clinical trial NCT03032965?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.